EP1355659A2 - Use of compositions containing pdgf-bb for promoting angiogenesis - Google Patents
Use of compositions containing pdgf-bb for promoting angiogenesisInfo
- Publication number
- EP1355659A2 EP1355659A2 EP02714757A EP02714757A EP1355659A2 EP 1355659 A2 EP1355659 A2 EP 1355659A2 EP 02714757 A EP02714757 A EP 02714757A EP 02714757 A EP02714757 A EP 02714757A EP 1355659 A2 EP1355659 A2 EP 1355659A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- pdgf
- fgf
- vegf
- angiogenesis
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 55
- 230000001737 promoting effect Effects 0.000 title claims abstract description 21
- 108010081589 Becaplermin Proteins 0.000 title claims description 116
- 239000000203 mixture Substances 0.000 title claims description 10
- 239000002870 angiogenesis inducing agent Substances 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 58
- 230000006444 vascular growth Effects 0.000 claims abstract description 8
- 239000003094 microcapsule Substances 0.000 claims description 61
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 52
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 47
- 229920002684 Sepharose Polymers 0.000 claims description 43
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 37
- 229920000669 heparin Polymers 0.000 claims description 37
- 229960002897 heparin Drugs 0.000 claims description 37
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 36
- 229940072056 alginate Drugs 0.000 claims description 36
- 235000010443 alginic acid Nutrition 0.000 claims description 36
- 229920000615 alginic acid Polymers 0.000 claims description 36
- 239000013598 vector Substances 0.000 claims description 34
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 25
- 238000002347 injection Methods 0.000 claims description 25
- 239000007924 injection Substances 0.000 claims description 25
- 239000011324 bead Substances 0.000 claims description 24
- 239000000560 biocompatible material Substances 0.000 claims description 21
- 208000028867 ischemia Diseases 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 229920000642 polymer Polymers 0.000 claims description 15
- 210000004204 blood vessel Anatomy 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 8
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims description 8
- 230000001177 retroviral effect Effects 0.000 claims description 8
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims description 7
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims description 7
- 238000002513 implantation Methods 0.000 claims description 7
- -1 cationic lipid Chemical class 0.000 claims description 6
- 239000010410 layer Substances 0.000 claims description 6
- 108010059616 Activins Proteins 0.000 claims description 5
- 102000009088 Angiopoietin-1 Human genes 0.000 claims description 5
- 108010048154 Angiopoietin-1 Proteins 0.000 claims description 5
- 102000009075 Angiopoietin-2 Human genes 0.000 claims description 5
- 108010048036 Angiopoietin-2 Proteins 0.000 claims description 5
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 5
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 5
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 5
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 5
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 5
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 5
- 101800004490 Endothelin-1 Proteins 0.000 claims description 5
- 108090000394 Erythropoietin Proteins 0.000 claims description 5
- 102000003951 Erythropoietin Human genes 0.000 claims description 5
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 5
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 5
- 108090000378 Fibroblast growth factor 3 Proteins 0.000 claims description 5
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 claims description 5
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims description 5
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 5
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims description 5
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims description 5
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 claims description 5
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 claims description 5
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 claims description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 5
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 5
- 108050009450 Neuropilin Proteins 0.000 claims description 5
- 102000002111 Neuropilin Human genes 0.000 claims description 5
- 108010081689 Osteopontin Proteins 0.000 claims description 5
- 102000004264 Osteopontin Human genes 0.000 claims description 5
- 102100040681 Platelet-derived growth factor C Human genes 0.000 claims description 5
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims description 5
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims description 5
- 239000000488 activin Substances 0.000 claims description 5
- 229940105423 erythropoietin Drugs 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims description 5
- 108010017992 platelet-derived growth factor C Proteins 0.000 claims description 5
- 102000005162 pleiotrophin Human genes 0.000 claims description 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 230000017531 blood circulation Effects 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- XEPXGZZWVKNRGS-GQYPCLOQSA-N n-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]octanamide Chemical compound CCCCCCCC(=O)NC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XEPXGZZWVKNRGS-GQYPCLOQSA-N 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- SCRCZNMJAVGGEI-UHFFFAOYSA-N 1,4-dioxane-2,5-dione;oxepan-2-one Chemical compound O=C1COC(=O)CO1.O=C1CCCCCO1 SCRCZNMJAVGGEI-UHFFFAOYSA-N 0.000 claims description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 3
- 229920000954 Polyglycolide Polymers 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 229950010732 poliglecaprone Drugs 0.000 claims description 3
- 239000004633 polyglycolic acid Substances 0.000 claims description 3
- 238000003259 recombinant expression Methods 0.000 claims description 3
- 239000002356 single layer Substances 0.000 claims description 3
- 102100033902 Endothelin-1 Human genes 0.000 claims 3
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 3
- 230000006698 induction Effects 0.000 claims 3
- 101150019331 FGF2 gene Proteins 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims 2
- 229920000936 Agarose Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 101150088952 IGF1 gene Proteins 0.000 claims 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 239000005038 ethylene vinyl acetate Substances 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920002492 poly(sulfone) Polymers 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 229940078499 tricalcium phosphate Drugs 0.000 claims 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims 1
- 235000019731 tricalcium phosphate Nutrition 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 28
- 108010082117 matrigel Proteins 0.000 description 28
- 230000002491 angiogenic effect Effects 0.000 description 25
- 241000700159 Rattus Species 0.000 description 22
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 22
- 210000004088 microvessel Anatomy 0.000 description 22
- 239000008188 pellet Substances 0.000 description 20
- 239000002775 capsule Substances 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 239000013613 expression plasmid Substances 0.000 description 16
- 239000003102 growth factor Substances 0.000 description 16
- 210000003098 myoblast Anatomy 0.000 description 15
- 230000003389 potentiating effect Effects 0.000 description 11
- 102000008076 Angiogenic Proteins Human genes 0.000 description 10
- 108010074415 Angiogenic Proteins Proteins 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000003489 abdominal muscle Anatomy 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 210000004087 cornea Anatomy 0.000 description 9
- 230000000302 ischemic effect Effects 0.000 description 9
- 238000011179 visual inspection Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 239000012148 binding buffer Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 7
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000005090 green fluorescent protein Substances 0.000 description 7
- 230000004217 heart function Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 208000010125 myocardial infarction Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010061216 Infarction Diseases 0.000 description 6
- 230000003187 abdominal effect Effects 0.000 description 6
- 230000003302 anti-idiotype Effects 0.000 description 6
- 230000007574 infarction Effects 0.000 description 6
- 210000005166 vasculature Anatomy 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 206010034576 Peripheral ischaemia Diseases 0.000 description 3
- 230000006427 angiogenic response Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 102400000686 Endothelin-1 Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 2
- 208000021328 arterial occlusion Diseases 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 239000011885 synergistic combination Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000000779 thoracic wall Anatomy 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000004792 Prolene Substances 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 230000026341 positive regulation of angiogenesis Effects 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Methods of promoting angiogenesis by delivering angiogenic factors are disclosed. The factors can be delivered as a gradient to a localized area of tissue to direct vascular growth.
Description
METHODS AND COMPOSITIONS FOR
PROMOTING ANGIOGENESIS
Background of the Invention This application claims priority to U.S. Provisional Patent Application Serial No.
60/264,457, filed on January 26, 2001, the contents of which are hereby incoporated herein.
Background of the Invention The depletion of oxygen supply to due to obstructed or inadequate blood supply is the common pathological state associated with various tissue ischemias, including myocardial ischemia, ischaemic bowel disease, and peripheral ischemia. The alleviation of tissue ischemia is critically dependent upon angiogenesis, the process by which new capillaries are generated from existing vasculature and tissue. The spontaneous growth of new blood vessels provide collateral circulation in and around an ischemic area, improves blood flow, and alleviates the symptoms caused by the ischemia. Although surgery or angioplasty may help to revascularize ischemic regions in some cases, the extent, complexity and location of the arterial lesions which cause the occlusion often prohibits such treatment. Alternative methods for the treatment of chronic ischemia have focused on the delivery of angiogenic growth factors, over twenty of which are known. To date, modest but significant angiogenesis has been achieved following administration (e.g., by local injection) of exogenous factors to animal models. For example, purified recombinant NEGF-A has been demonstrated to elicit a modest but significant vascularization following injection into ischemic skeletal muscle tissue in a rabbit model of chronic limb ischemia [Takeshita et al, Circulation 90, 228:1994]. In addition, direct injection of vectors containing cDΝA encoding NEGF-A has also been shown to induce a modest stimulation of angiogenesis in ischemia animal models in both skeletal and cardiac muscle [Takeshita et al, Biochemical and Biophysical Research Communications 227, 628:1996; and MacGovern et al., Human Gene Therapy 8, 215: 1997]. However, such local application often results in diffusion of the factors away from the desired site, thus diminishing angiogenic effect. Moreover, it is known that such bolus delivery of angiogenic factors generally results in a local and disorganized hodge-podge of new blood vessels, only a fraction of which (if any) contribute to amelioration of a blockage.
An additional limitation associated with current approaches for promoting angiogenesis and effective treatment of ischemia is the inability of stable blood vessels to form by application of single agents using known techniques. In past studies, when vessels were followed for several months after treatment of ischemic animal models, the vast majority of new vessels were observed to regress after the applied growth factor had become depleted. Thus, current approaches for ischemia therapy require repeated applications of factors to maintain newly formed vasculature.
Other related therapy methods attempt to circumvent the need for multiple applications by relying on the transplantation of autologous or non-autologous cells which can produce sustained levels of angiogenic proteins. In one such approach, a subject's endogenous cells are isolated, cultured, and transfected with expression vectors encoding angiogenic proteins. Following in vitro manipulations, these cells are injected back into the patient at the site of tissue ischemia. However, the drawbacks of this approach include the time and effort required to isolate, culture and transfect target cells from each individual patient, as well as difficulties in securing sustained expression of angiogenic proteins. In addition, sub-optimal cell survival and differentiation states of the cells following injection also limit the efficacy and of this approach.
To avoid these problems, cells have been obtained from non-patient (e.g., allogeneic), even non-human, sources and manipulated in the manner described above. However, the modified non-patient or non-human cells are often rejected by the patient's own immune system, making this approach impractical too.
Accordingly, improved therapies for promoting tissue angiogenesis and generating stable vasculature in a safe, reliable, and non-invasive manner are needed to treat tissue ischemia and other related conditions.
Summary of the Invention
The present invention provides novel methods and compositions for promoting angiogenesis to treat a variety of tissue ischemias, including peripheral and myocardial ischemia. Selected angiogenic factors or synergistic combinations of factors, functional analogues of such factors or combinations of factors, or nucleic acids encoding such factors or combinations of factors, are delivered to a localized area of tissue in an amount effective to induce angiogenesis within the area of tissue. The invention further includes improved methods and vehicles for delivering such factors or combinations of factors, functional analogues of such factors or combinations of factors, and nucleic acids encoding such factors or combinations of factors.
In one embodiment, the invention provides a method of promoting angiogenesis comprising delivering PDGF-BB to a localized area of tissue in an amount effective to induce angiogenesis within the area of tissue. The PDGF-BB can be delivered either alone or in combination with another angiogenesis-promoting factor, particularly bFGF and/or NEGF-A. The angiogenesis-promoting factor or combination of factors can be administered in the form of a protein composition or an expression plasmid encoding the protein(s). The angiogenesis-promoting factor or combination of factors can also be administered in the form of functional analogues of the factor or combination of factors. For example, anti-idiotypic antibodies of PDGF-BB, NEGF-A and/or bFGF can be administered in accordance with the invention.
When administering the angiogenesis promoting factors of the invention in the form of an expression plasmid, suitable vectors include, but are not limited to, adenoviral vectors, retroviral vectors, adeno-associated viral vectors, RΝA vectors, liposomes, cationic lipids, lentiviral vectors and transposons. In another embodiment, the invention provides a method for promoting angiogenesis by delivering angiogenic factors, such as those described above, to a localized area of tissue using heparin sepharose-containing microcapsules in an amount effective to induce angiogenesis within the area of tissue. The angiogenic factors or expression plasmids encoding the factors are incorporated into the microcapsules as described in the working examples provided below for slow, sustained release into localized areas of tissue.
In a particular embodiment, the microcapsules are made up of uncoated heparin sepharose beads, heparin sepharose beads coated with a single layer of alginate polymer, heparin sepharose beads coated with poly-ethylene glycol (PEG) polymer or heparin sepharose beads coated with alternating layers of alginate and PEG. Typically, the microcapsules range in size from 1-200 microns.
Suitable angiogenic factors for incorporating into the microcapsules include, for example, M-CSF, GM-CSF, NEGF-A, VEGF-B, VEGF-C, NEGF-D, VEGF-E, neuropilin, FGF-1 , FGF-2(bFGF), FGF-3, FGF-4, FGF-5, FGF-6, PDGF-BB, PDGF- AA, Angiopoietin 1, Angiopoietin 2, erythropoietin, BMP-2, BMP-4, BMP-7, TGF- beta, IGF-1, Osteopontin, Pleiotropin, Activin, Endothelin-1, and combinations thereof or an expression vectors encoding such angiogenic factors. The angiogenic factors can be purified from their native sources or produced by recombinant expression.
The microcapsules are contacted with the localized area of tissue generally by injection or surgical implantation. For example, injection can be performed using a catheter based trans-myocardial injection technology, such as the ΝOGA technology.
In yet another embodiment, the present invention provides a method for promoting angiogenesis by contacting a localized area of tissue with a gradient of one or more angiogenic factors or a nucleic acid encoding one or more angiogenic factors, such that directed vascular growth along the gradient is achieved. Such directed vascular growth can be used to achieve interconnection and/or intraconnection of blood vessels (e.g., to circumvent blood flow around a blockage within a blood vessel).
In a particular embodiment, the angiogenic factor or nucleic acid is released in a gradient using a biocompatible material which is contacted with (e.g., implanted within) the localized area of tissue. The angiogenic factor is associated with the biocompatible material (e.g., absorbed onto the biocompatible material) such that it is released onto surrounding tissue. This can be achieved by treating the biocompatible material with the angiogenic factor prior to contact with (e.g., implantation into) a selected area of tissue. The angiogenic factor is then released from the biocompatible material onto the surrounding tissue in a directed gradient determined by the placement of the biocompatible polymer
Suitable biocompatible materials include, for example, polymers or threads which incorporate the angiogenic factor. In a preferred embodiment, the biocompatible material is an absorbable thread, such as polyglyconate monofilament, poliglecaprone 25-(Monocryl), polydiaxonone (PDS II), polyglactin 910, polyglycolic acid, Biodyn glycomer 631, chromic surgical gut or plain surgical gut.
These and other embodiments of the invention are described in the following figure detailed description, examples and figures.
Brief Description of the Figures Figure 1 is a graph comparing levels of angiogenesis in the Matrigel model using a low dose of transduced cells encoding GFP alone (control), NEGF-A, NEGF-C, NEGF-D bFGF or PDGF-BB. C57B1/10 mice were each injected subcutaneously into the abdominal with a low dose of 3 x 105 retrovirally transduced autologous myoblast cells, suspended in 0.4ml of Matrigel. Mice were sacrificed 13 days later and the matrigel pellet and a section of the abdominal muscle adjacent to the pellet was removed. Samples were sectioned and the number of microvessels in the abdominal muscle was quantified by visual inspection of sections under the microscope. Shown is the number of microvessels per 10 high power fields counted. The most potent angiogenic effect was observed with NEGF-A, PDGF-BB and bFGF. Analysis of the dose response curve for PDGF-BB and VEGF-A transduced cells showed that PDGF- BB was more potent than VEGF-A at lower doses.
Figure 2 is a graph comparing levels of angiogenesis in the Matrigel model using a high dose of cells transduced to express bFGF, NEGF-A and PDGF-BB. C57B1/10 mice were each injected with a high cell dose of 2 x 106 retrovirally transduced autologous myoblast cells suspended in 0.4ml of Matrigel. Mice were sacrificed 13 days later, the pellets were recovered, sectioned and the number of microvessels counted by visual inspection. Shown are the number of microvessels per 10 high power fields. At this cell dose, PDGF-BB was as potent as either bFGF or NEGF-A at stimulating angiogenesis.
Figure 3 shows photographs of mouse corneas 6 days following the implantation of pellets coated with control saline (A), PDGF-BB (B), NEGF-A (C) or bFGF (D) alone. Bottom panels: Quantification of the angiogenic effect elicited by each factor. Vessel length (E), clock hours (F) and area (G) are shown.
Figure 4 (A) shows photographs of mouse corneas 6 days following the implantation of pellets coated with VEGF-A alone (left panel), bFGF (middle panel) or both factors combined (right panel). (B) shows the quantification of the angiogenic effect elicited by each growth factor in terms of clock hours (left panel), vessel length (middle panel) and area (right panel).
Figure 5 (top panels) shows photographs of mouse corneas 6 days post- transplantation of pellets coated with bFGF alone (left panel) or bFGF combined with PDGF-BB (middle and right panels). Bottom panels show photographs of mouse corneas 6 days post-transplantation of pellets coated with either VEGF-A alone (left panel) or VEGF-A combined with PDGF-BB (right panel).
Figure 6 is a graph comparing the quantification of angiogenesis in the mouse cornea model using PDGF-BB, VEGF-A or bFGF either alone or in combination. Corneal micropockets were created with a cataract knife in the eyes of 8-week old C57B1/6 mice. Into this pocket, aluminum sulfate pellets coated with between 80 and 160ng of recombinant human PDGF-BB, VEGF-A, bFGF or combinations thereof were implanted and mice were monitored daily. A total of 5 mice were transplanted per group. The area of newly grown vessels was assessed 5 days post implantation. Mice implanted with control pellets showed no evidence of angiogenesis. When tested alone, bFGF stimulated the highest level of angiogenesis followed by VEGF-A and PDGF-BB. The level of angiogenesis stimulated by VEGF-A in combination with PDGF-BB was equivalent to that observed for bFGF alone. Unexpectedly, the most potent combination
was PDGF-BB and bFGF. Of all combinations tested, PDGF-BB and bFGF together stimulated the greatest level of angiogenesis, significantly greater than that observed for VEGF-A and bFGF.
Figure 7 is a schematic illustration of the experimental strategy to make heparin sepharose/alginate microcapsules. Heparin sepharose beads (Pharmacia: 50- 150 Dm in size) are mixed with a solution of sodium alginate to a final concentration of 200mg/ml. The heparin sepharose/alginate solution is then loaded into a 5ml syringe and slowly injected into a coaxial airflow system constructed at Genetix. The coaxial air flow creates a mist of the heparin sepharose/alginate solution which drops into a 1.5% calcium chloride bath. Once the alginate hits the calcium solution the alginate becomes cross-linked, forming a solid gel capsule roughly in the shape of a sphere. The size of the microcapsules can vary greatly from 50 - 400 Dm. Large microcapsules (greater than 200 Dm in size) are removed from the capsule mixture using a 200 Dm sieve. Once formed the capsules are washed twice in sterile water and stored in buffer composed of 0.9% sodium chloride and ImM calcium chloride. Capsules are loaded with recombinant human PDGF-BB by incubation in binding buffer (0.9% NaCl, ImM CaC12 and 0.05% gelatin) at 4°C overnight (-16 hours) with gentle shaking. The next day the capsules are removed, washed twice in binding buffer and either cultured in vitro to determine the kinetics of PDGF-BB release or injected in vivo to assess angiogenesis. The efficiency of PDGF-BB uptake is quantified by ELISA of the binding buffer following removal of the capsules.
Figure 8 is a graph showing that heparin sepharose/alginate capsules bind large amounts of recombinant human PDGF-BB. Shown is the amount of PDGF-BB absorbed by 3000 capsules following incubation with various quantities of growth factor. The amount of PDGF-BB remaining in the binding buffer following incubation with capsules was quantified by ELISA. Three thousand capsules were able to absorb at least 35 μg of PDGF-BB representing 13 ng of PDGF-BB per capsule.
Figure 9 is a graph showing that heparin sepharose/alginate microcapsules provide slow, high level and long term release of bound PDGF-BB in vitro. Ten μg of recombinant human PDGF-BB was incubated with three different types of test samples. The first test sample was composed of non-encapsulated heparin sepharose beads while the second and third groups were composed of alginate encapsulated heparin sepharose beads made using either a 1.2% or a 1.6% alginate solution. Three thousand beads/microcapsules were incubated with PDGF-BB at 4°C overnight with gentle
shaking. ELISA analysis of the binding buffer the next day showed absorption of 90% (9μg) of the PDGF by the capsules. Following incubation with PDGF-BB, the beads/microcapsules were washed, resuspended in 5mls of serum free medium and incubated at 37°C. Every 24 hours the medium was changed and the amount of PDGF- BB present in the medium quantified by ELISA. A slow, sustained release of approximately 0.5-3% of the total bound PDGF-BB (representing 125-250ng) was detected each day for a minimum of 14 days, the longest time point tested. Importantly, the proportion of PDGF-BB released per day is equivalent to the amount of PDGF-BB that was estimated to be secreted by muscle cells transduced with the PDGF-BB retro virus in the foregoing Matrigel experiments. The release kinetics for non- encapsulated heparin sepharose beads was better than those observed for the alginate encapsulated heparin sepharose.
Figure 10 is a graph showing that PDGF-BB microcapsules potently stimulate angiogensis in vivo in the stringent Matrigel model. Three thousand microcapsules loaded with lμg or lOμg of PDGF-BB were mixed with 400μl of Matrigel and subcutaneously injected into the abdominal region of C57B1/10 mice. Thirteen days later mice were sacrificed, the pellets and a section of the adjacent abdominal muscle was removed, fixed, sectioned and the number of microvessels quantified by visual inspection of the sections under the microscope. The results showed that the number of microvessels in mice receiving microcapsules loaded with lOmg of PDGF-BB was 2.5- fold greater than that of control mice.
Figure 11 is a graph showing that PDGF-BB microcapsules stimulate angiogenesis in infarcted rat hearts 3 weeks post-injection. Infarcted rat hearts were injected with 1600 microcapsules containing μg (control) or 18μg of PDGF-BB in a volume of 20μl. Three weeks post injection rats were sacrificed, hearts were removed, fixed, sectioned and the number of microvessels within the infarct region quantified by visual inspection under a microscope. Shown is the number of microvessels per 5 high power fields for recipients of control and PDGF-BB microcapsules. Rats injected with PDGF-BB microvessels showed an approximate 2-fold increase in the number of microvessels as compared to control rats.
Figure 12 shows an analysis of cardiac function in rats injected with control vs. PDGF-BB microcapsules following myocardial infarction. Left ventricular pressure (LVP), dP/dT, neg dP/dT and tau were measured prior to sacrifice at 3 weeks post injection. Left ventricular pressure (LNP) is the maximum pressure in the left ventricle
during contraction. The dP/dT variable is the first derivative of the pressure wave and is separately viewed for the upstroke (dP/dT) and the downstroke (neg dP/dT). The upstroke (dP/dT) is a measure of contractility and reflects the condition of the muscle independent of the pressure. Neg dP/dT reflects the relaxation of the muscle, which together with the relaxation constant, tau, provides information on the stiffness of the ventricular wall following infarction. A significant improvement in all parameters was detected in rats injected with PDGF-BB microcapsules. Rats injected with PDGF-BB microcapsules showed a 25% increase in left ventricular pressure, a 2-3 fold increase in cardiac contractility/relaxation and a 2.5-3 fold decrease in the relaxation constant tau.
Figure 13 is a graph showing that PDGF-BB and bFGF delivered by slow release microcapsules potently synergize to stimulate angiogensis in vivo in the stringent Matrigel model. Three thousand microcapsules loaded with lμg of bFGF were mixed with 400μl of Matrigel and subcutaneously injected into the abdominal region of C57B1/10 mice. Thirteen days later mice were sacrificed, the pellets and a section of the adjacent abdominal muscle was removed, fixed, sectioned and the number of microvessels quantified by visual inspection of the sections under the microscope. The results showed that the number of microvessels in mice receiving bFGF + PDGF-BB microcapsules was 4-fold greater than that of mice implanted with either growth factor alone.
Figure 14 is a schematic illustration of the structure of various angiogenic expression plasmids. All vectors were constructed using the pCI vector backbone from Promega. All vectors contained the Cytomegalovirus immediate-early enhancer/promoter region, a chimeric intron and the late poly adenylation signal from SV40. The cDNA encoding either human PDGF-BB, NEGF-A or bFGF was inserted into this vector downstream of the chimeric intron. A cDΝA encoding for the mature PDGF-BB protein was cis-linked to the secretory signal from the murine IgGkappa immunoglobulin light chain gene while the NEGF-A cDΝA utilized its endogenous secretory signal. Since endogenous bFGF is not secreted by the usual Golgi pathway and prior groups have had difficulty in obtaining high level secretion of bFGF from cells transduced with the bFGF cDΝA, the bFGF cDΝA was linked in cis to the secretory signal from the human Interleukin-2 cDΝA. The level of angiogenic protein secreted from transiently transfected 293T cells, as assessed by ELISA, is shown to the right. To analyze cardiac function in rats injected with control vs. PDGF-BB expression plasmids following myocardial infarction, test animals are anesthetized and intubated. The chest wall is opened and a myocardial infarct is created by tying off the anterior descending
artery. 180μg of control or test expression plasmid is injected into the heart wall in a volume of 20μl. Cardiac function is assessed 3 weeks post injection. Animals are sacrificed, the heart is removed and efficiency of plasmid uptake is assessed by staining with X-gal. The size of the infarct and the extent of angiogenesis is quantified.
Detailed Description of the Invention
While growth promoting factors have been described as an angiogenic agents, the efficacy of such proteins as a therapeutic agents for the treatment of peripheral and/or myocardial ischemia has not yet been demonstrated. The present invention provides, for the first time, methods for promoting angiogenesis and treating such ischemia using particular angiogenic factors, such as PDGF-BB, as well as particular combinations of factors (e.g., combinations which include PDGF-BB). The present invention also provides improved methods for delivering the factors to increase their efficacy, for example, by enabling directed and/or controlled release of the angiogenic factors onto surrounding tissue (e.g., ischemic myocardium).
ANGIOGENIC FACTORS
As used herein, the term "angiogenic factor" refers to any known protein factor capable of promoting growth of new blood vessels from existing vasculature ("angiogenesis"). Suitable angiogenic factors for use in the invention include, for example, PDGF-BB, PDGF-AA, M-CSF, GM-CSF, NEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, neuropilin, FGF-1 , FGF-2(bFGF), FGF-3, FGF-4, FGF-5, FGF-6, Angiopoietin 1, Angiopoietin 2, erythropoietin, BMP-2, BMP-4, BMP-7, TGF-beta, IGF-1, Osteopontin, Pleiotropin, Activin, Endothelin-1 and combinations thereof. The term "angiogenic factor" also refers to functional analogues of the above- mentioned factors. Such functional analogues include, for example, functional peptides or portions of the factors. Functional analogues also include anti-idiotypic antibodies which bind to the receptors of the factors and, thus, mimic the activity of the factors in promoting angiogenesis. Methods for generating such anti-idiotypic antibodies are well known in the art and are described, for example, in WO 97/23510, the contents of which are incorporated by reference herein.
Antigens have specific epitopes to which certain antibodies will bind. The region of the antibody that specifically interacts with the epitopes on the antigen is called the antigen combining site. The antigen combining site is composed of a collection of idiotopes which are unique sequences on the antibody that specifically interact with the epitopes on the antigen. The specific collection of idiotopes that interact with the epitopes on the antigen is defined as an antibody's "idiotype". Accordingly, an anti-
idiotype antibody is an antibody that is directed against the antigen combining site of the first antibody. Anti-idiotype antibodies combine with those specific sequences and may resemble or act as the epitope to which the first antibody reacts. For example, one can have an antibody that binds to specific epitopes on bFGF. One can then make a second antibody (an anti-idiotype antibody) that specifically interacts with antigen combining site of the first antibody. This anti-idiotype antibody may then mimic the biological activity of bFGF itself by binding to the bFGF receptor and activating it.
The use of anti-idiotype antibodies (as growth factor analogues) in the methods of the present invention can be advantageous in that many growth factors have a very short half life and therefore most of the factor that is given to a patient is not utilized. In contrast, antibodies have much greater half lives and therefore their potency is maintained for a greater length of time in vivo. In addition the levels of growth factors that are required to achieve a biological effect can, in certain instances, produce adverse reactions such as toxicity and hypotension. Since lower levels of anti-idiotype antibodies may be required to produce the same biological effect these adverse side effects may be prevented.
Angiogenic factors used in the present invention can be purified from their native sources or produced by recombinant expression and subsequently administered to patients as a protein composition. Alternatively, the factors can be administered in the form of an expression plasmid encoding the factors, as is described in further detail below. The construction of suitable expression plasmids is well known in the art. Particular angiogenic expression plasmids for use in the invention are shown in Figure 14 and are described in Example 1. Suitable vectors for constructing expression plasmids include, for example, adenoviral vectors, retroviral vectors, adeno-associated viral vectors, RNA vectors, liposomes, cationic lipids, lentiviral vectors and transposons. Accordingly, in one embodiment, the present invention provides novel methods and compositions for promoting angiogenesis to promote angiogenesis and to treat a variety of tissue ischemias. Selected angiogenic factors or synergistic combinations of factors, functional analogues of such factors or combinations of factors, or nucleic acids encoding such factors or combinations of factors, are delivered to a localized area of tissue in an amount effective to induce angiogenesis within the area of tissue.
In a preferred embodiment, the invention provides a method of promoting angiogenesis comprising delivering PDGF-BB to a localized area of tissue in an amount effective to induce angiogenesis within the area of tissue. The PDGF-BB can be delivered either alone or in combination with another angiogenesis-promoting factor. Particularly preferred combinations include PDGF-BB combined with bFGF and/or VEGF-A.
DELIVERY VEHICLES FOR ANGIOGENIC FACTORS
I. In another embodiment, the present invention provides a means for delivering angiogenic factors to a localized area of tissue in a controlled, sustained fashion. One problem in using purified (e.g., recombinant) angiogenic proteins to stimulate angiogenesis for the treatment of myocardial and peripheral tissue ischemia can be the short half-life of the protein upon injection in vivo. This problem is addressed by way of the present invention using slow-release heparin sepharose-containing microcapsules in an amount effective to induce angiogenesis within the area of tissue. One property that many angiogenic factors share is the ability to bind to heparin, a highly sulfated glycosaminoglycan that plays a role in anti-coagulation in vivo. This property is exploited in making the heparin sepharose containing microcapsules of the present invention which bind angiogenic factors and provide slow release of the factors when contacted (e.g., implanted) with localized tissue. The experimental process for making the microcapsules is described in detail in Example 3 and shown schematically in Figure 7.
In one embodiment, the microcapsules are injected or surgically implanted into localized areas of tissue. In another embodiment, the microcapsules are delivered to localized areas of tissue using the NOGA system (Biosense). NOGA is a 3 dimensional catheter based transmyocardial injection system. A catheter is inserted into a major vein/artery and is snaked up into either of the ventricals of the heart. The end of the catheter contains a needle and a space in which therapeutic agents can be inserted and subsequently injected intra-myocardially into the damaged areas of the heart muscle. This delivery method is much easier and safer for the patient and is much more efficacious than other methods of delivery including intracoronary injections or placing therapeutic agents against the wall of the heart. Due to the nature of the system, only therapeutic agents which can be physically delivered through a 25-27 gauge needle can be used. Thus macrocapsules described in the prior art cannot be used with such a system, whereas microcapsules of the present invention can be used with the system. The microcapsules are composed of single heparin sepharose beads which optionally can be coated with a thin layer of alginate polymer. In a particular embodiment of the invention, the microcapsules are made up of uncoated heparin sepharose beads, heparin sepharose beads coated with a single layer of alginate polymer, heparin sepharose beads coated with poly-ethylene glycol (PEG) polymer or heparin sepharose beads coated with alternating layers of alginate and PEG.
Using, for example, the coaxial air flow technology shown in Figure 7 and described in Example 1, the microcapsules can also be made small enough for use in the
NOGA delivery system. For example, the microcapsules typically range from 1-200 microns in size. Moreover, they are able to absorb large quantities of angiogenic factors, such as FGF-2, VEGF-A and PDGF-BB, and slowly release the factors over extended periods of time at levels which are able to stimulate the growth of new blood vessels in vivo.
II. In another embodiment, the present invention provides a means for delivering angiogenic factors to a localized area of tissue using a gradient of one or more angiogenic factors or a nucleic acid encoding one or more angiogenic factors, such that directed vascular growth along the gradient is achieved. Angiogenic factors, such as those described in the preceding examples, work by providing a gradient of angiogenic factor that stimulates the chemotaxis and proliferation of endothelial cells, and their supporting cells towards the source of the factor. Regulating the growth of new vessels from existing vasculature (angiogenesis) that effectively bypass an arterial lesion requires strict spatial and temporal control. Accordingly, by forming a directed gradient of angiogenic factors in accordance with the present invention, interconnection and/or intraconnection of blood vessels (e.g., to circumvent blood flow around a blockage within a blood vessel) can be achieved.
In a particular embodiment, the angiogenic factor (or a nucleic acid encoding the factor) is released in a gradient using a biocompatible material which contains the factor such that the factor is released onto surrounding tissue when the biocompatible material is contacted with (e.g., implanted within) the tissue. This can be achieved by treating the biocompatible material with the angiogenic factor prior to contact with (e.g., implantation into) a selected area of tissue in a manner which allows for release of the factor from the material in vivo. The biocompatible material is then contacted with (e.g., implanted into) a localized area of tissue in a configuration which provides a directed gradient of the angiogenic factor once it is released from the material.
Suitable biocompatible materials for use in the invention include, for example, polymers or threads which incorporate the angiogenic factor. In a preferred embodiment, the biocompatible material is an absorbable thread, such as polyglyconate monofilament, poliglecaprone 25-(Monocryl), polydiaxonone (PDS II), polyglactin 910, polyglycolic acid, Biodyn glycomer 631, chromic surgical gut or plain surgical gut. The biocompatible material can be coated with one or several angiogenic factors to allow delivery of growth factor or growth factor combinations that provide the optimal angiogenic stimulus. The biocompatible material can also be engineered to release certain growth factors at specific rates and at specific times that may help mimic the natural angiogenic process more closely.
The invention is further illustrated by the following examples which should not be construed as limiting.
EQUIVALENTS
Although the invention has been described with reference to its preferred embodiments, other embodiments can achieve the same results. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific embodiments described herein. Such equivalents are considered to be within the scope of this invention and are encompassed by the following claims.
INCORPORATION BY REFERENCE
The contents of all references and patents cited herein are hereby incorporated by reference in their entirety.
EXAMPLES
The following examples were perfomed to demonstrate and quantify the angiogenic potential of PDGF-BB alone and in combination with other angiogenic factors. A variety of assays were used, including the stringent Matrigel assay, the mouse cornea assay, and the ischemic rat heart assay, all as described in detail below.
EXAMPLE 1 - Construction of Retroviral Vectors Containing Angiogenic cDNAs , Analysis of Virus Titer and Assessment of Stable Gene Transfer
In order to provide stable, high-level delivery of PDGF-BB in the Matrigel model, primary myoblasts from C57B1/10 mice were transduced with retroviral vectors encoding human PDGF-BB. To compare the angiogenic potential of PDGF-BB to other known angiogenic agents, retroviral vectors encoding human VEGF-A165, VEGF-C, VEGF-A, VEGF-D, PDGF-BB, or bFGF also were constructed and tested. All vectors are shown schematically in Figure 14. Since VEGF-C, VEGF-D and PDGF-BB cDNAs encode proteins which are inactive (or less active in the case of PDGF-BB) in their non- processed form, vectors containing cDNAs encoding the mature forms of the aforementioned proteins linked to the powerful secretory signal from the murine IgG kappa immunoglobulin gene were constructed.
All vectors also contained the gene encoding the green fluorescent protein (GFP) to enable the fast efficient and non-toxic selection of transduced target cells by fluorescence activated cell sorting (FACS). FACS sorting is used to isolate the brightest
10% of GFP positive retrovirally transduced cells. Since both GFP and the angiogenic cDNA are translated from the same mRNA molecule, this ensures that the sorted cells also express high levels of the angiogenic protein. A strong correlation between the fraction of top GFP expressing cells and the amount of angiogenic protein secreted by the sorted cells exists. This result, in combination with data from Southern blot analysis of transduced cells which showed 3-6 proviral copies per genome in sorted GFP positive cells, indicates that the levels of angiogenic protein production and secretion are at their maximal level using this system.
All vectors were tested for stability of gene transfer and virus titer. Vectors demonstrated a virus titer ranging from approximately 5 x 105 - 1.2 x 106 infectious virus particles per ml and all vectors showed stable transfer of the angiogenic cDNA to target primary skeletal muscle myoblasts from C57B1/10 mice. To enable the easy localization and quantification of transduced myoblasts following injection in vivo, all myoblast samples were also marked by infection with a retroviral vector encoding a β- galactosidase/neomycin (β-GEO) resistance fusion gene.
I. Characterization of the Protein Expression and Secretion Properties of
Retrovirally Transduced C57B1/10 Myoblasts
High-level expression and secretion of the encoded angiogenic proteins from transduced myoblast cells was demonstrated by either Western blot or ELISA analysis of supernatants from virally transduced myoblasts.
Angiogenic Factor Amount of Protein Secreted (ng/1 x 106 cells/24 hours)
VEGF-A 88
VEGF-C 790
VEGF-D 580
PDGF-BB 56 bFGF 20
EXAMPLE 2 - Quantification of Angiogenic Stimulation by Transduced Myoblasts
Using the Stringent Matrigel Assay
The potency of the angiogenic proteins secreted from the transduced myoblasts described in Example 1 was assessed in vivo using the stringent Matrigel assay. In brief, 3 x 105 - 2 x 106 transduced myoblasts were suspended in Matrigel and injected subcutaneously into the dorsal abdominal region of C57B1/10 mice. The Matrigel pellets, in addition to a section of abdominal muscle adjacent to the Matrigel pellet, were
recovered 13 days post-injection. Following harvesting of the Matrigel pellet and the adjacent abdominal muscle 13 days post-injection, Matrigel pellets were stained with X- gal and analyzed for the presence of blue, retrovirally transduced myoblasts. In addition, the number of microvessels in the adjacent abdominal muscle was quantified by visual inspection.
A significant (p< 0.05) angiogenic response was observed for VEGF-A, VEGF- C, PDGF-BB, and bFGF (see Figures 1 and 2). Transplantation transduced myoblasts secreting the aforementioned growth factors resulted in approximately a 4-5-fold increase in the number of microvessels observed. The most potent angiogenic response was observed for PDGF-BB, followed by VEGF-A and bFGF (Figures 1 and 2).
EXAMPLE 3 - Assessment of the Angiogenic Potential of PDGF-BB using the Mouse Cornea Model
The potential of factors, such as PDGF-BB, as angiogenic agents was also investigated using the mouse cornea model. Corneal micropockets were created with a cataract knife in the eye of 8-week old C57B1/6 mice. Into this pocket, a 0.34mm X 0.34mm sucrose aluminum sulfate pellet coated with hydron polymer containing 160ng of recombinant human PDGF-BB, 160ng of human VEGF-A, or 80 ng of human bFGF was implanted and mice were monitored daily. While those mice implanted with control pellets showed no evidence of angiogenesis, all mice receiving PDGF-BB coated pellets showed evidence of potent angiogenesis (see Figure 3). Thus, recombinant PDGF-BB protein can potently stimulate the growth of new vessels in both the mouse Matrigel and corneal assays. In contrast to the results obtained using the Matrigel assay, PDGF-BB by itself, although inducing a clear and potent angiogenic response, was less potent than either VEGF-A or bFGF (Figure 3). The differences observed for the Matrigel and mouse corneas models could be explained by the production of additional endogenous angiogenic factors by transduced myoblasts that synergize more readily with PDGF-BB compared to VEGF-A. Alternatively, the levels of recombinant VEGF-A and PDGF- BB produced in vivo may differ to the levels produced in vitro. Unexpectedly, the combination of bFGF and PDGF-BB proved to be, by far, the most potent combination (Figure 5), producing an angiogenic effect many times greater than the any factor alone (Figure 3) or bFGF and VEGF-A combined (Figure 4). Moreover, the level of this synergistic effect appeared to be specific to PDGF-BB and bFGF since PDGF-BB combined with VEGF-A did not elicit nearly as potent an effect (see Figure 6). Therefore, the most potent combination of angiogenic factors observed was PDGF-BB and bFGF.
EXAMPLE 4 - Therapeutic Effect of PDGF-BB Delivered Via Slow Release Microcapsules for the Treatment of Myocardial Ischemia
The following studies were performed to assess the ability of PDGF-BB to promote angiogenesis in vivo in the stringent Matrigel model and to improve cardiac function in ischemic rat models having myocardial infarction, using a slow release delivery system employing heparin-sepharose/alginate microcapsules. This delivery approach was based upon the ability of certain factors, such as bFGF and PDGF-BB, to bind strongly to heparin molecules both in vitro and in vivo. Sepharose beads coated with heparin (approximately 50-150μm in size) were purchased from Pharmacia. The beads were sterilized using UV irradiation and mixed with a 1.6% solution of alginate polymer. This polymer is able to form gels through chemical cross-linking with multivalent cations such as calcium. The procedure for making heparin-sepharose/alginate capsules, shown in Figure 7, was as follows. Sterilized heparin-sepharose beads were mixed with a 1.6% alginate solution and the mixture was loaded into a 5ml syringe. The mixture was then extruded through a needle and a mist of heparin sepharose/alginate, produced using a coaxial air flow system, dropped into a wash bath of 1.5% calcium chloride solution. Once the alginate hit the calcium solution, the alginate became cross-linked, forming a solid gel capsule in the shape of a sphere. Once formed, the capsules were forced through a 250μm sieve, washed twice in sterile water and stored in buffer composed of 0.9% sodium chloride and ImM calcium chloride. Visual analysis of the capsules under the microscope showed that the vast majority of microcapsules were composed of individual heparin sepharose beads coated with a thin layer of alginate. Heparin-sepharose/alginate microcapsules were incubated overnight at 4 degrees
Celcius in binding buffer composed of 0.9% sodium chloride, ImM calcium chloride, 0.05% gelatin and lOμg of recombinant PDGF-BB for 16 hours. The next day, the binding buffer was removed from the microcapsules and analyzed by ELISA to quantify the amount of PDGF-BB absorbed by the capsules. In a typical experiment, approximately 75-90% of the PDGF-BB protein is absorbed by the microcapsules (see Figure 8). Next, the heparin-sepharose/alginate microcapsules were washed twice in fresh binding buffer and either placed in vitro to assess release kinetics or injected into the myocardium of rats that had undergone surgically induced myocardial infarction. To assess the release kinetics of the bound PDGF-BB in vitro, three thousand heparin-sepharose/alginate microcapsules or three thousand non-alginate encapsulated heparin sepharose beads containing 9μg of bound PDGF-BB were placed in serum free
medium and incubated at 37 degrees Celcius. Every 24 hours the medium was changed and the amount of PDGF-BB present in the medium quantified by ELISA. The results showed a slow, sustained release of approximately 0.5-3% of the total bound PDGF-BB for a minimum of 14 days, the longest time point analyzed (see Figure 9). Importantly, the proportion of PDGF-BB released per day was equivalent to the amount of PDGF-BB that we estimated to be secreted by muscle cells transduced with the PDGF-BB retrovirus in the Matrigel experiments described in Example 1.
The ability of the heparin-sepharose/alginate microcapsules to stimulate angiogenesis in vivo was assessed using the stringent Matrigel assay. Three thousand microcapsules loaded with 1 μg or 1 Oμg of PDGF-BB were mixed with 400μl of Matrigel and subcutaneously injected into the abdominal region of C57B1/10 mice. Thirteen days later mice were sacrificed, the pellets and a section of the adjacent abdominal muscle was removed, fixed, sectioned and the number of microvessels quantified by visual inspection of the sections under the microscope. As shown in Figure 10, the number of microvessels in mice receiving microcapsules loaded with lOmg of PDGF-BB was 2.5-fold greater than that of control mice.
In addition, as shown in Figure 13, PDGF-BB and bFGF delivered by slow release microcapsules synergize to stimulate angiogensis in vivo in the stringent Matrigel model. Three thousand microcapsules loaded with lμg of bFGF were mixed with 400μl of Matrigel and subcutaneously injected into the abdominal region of
C57B1/10 mice. Thirteen days later mice were sacrificed, the pellets and a section of the adjacent abdominal muscle was removed, fixed, sectioned and the number of microvessels quantified by visual inspection of the sections under the microscope. Figure 13 shows that the number of microvessels in mice receiving bFGF + PDGF-BB microcapsules was 4-fold greater than that of mice implanted with either growth factor alone.
PDGF-BB microcapsules were also tested for their ability to stimulate angiogenesis in infarcted rat hearts 3 weeks post-injection. Infarcted rat hearts were injected with 1600 microcapsules containing μg (control) or 18μg of PDGF-BB in a volume of 20μl. Three weeks post injection rats were sacrificed, hearts were removed, fixed, sectioned and the number of microvessels within the infarct region quantified by visual inspection under a microscope (i.e., number of microvessels per 5 high power fields for recipients of control and PDGF-BB microcapsules). As shown in Figure 11, rats injected with PDGF-BB microvessels showed an approximate 2-fold increase in the number of microvessels as compared to control rats.
The ability of the heparin-sepharose/alginate microcapsules to stimulate angiogenesis in vivo was also assessed using the ischemic rat heart model as follows. Adult male rats were anesthetized, intubated and ventilated with a Harvard respirator. Under sterile conditions, a left lateral thoractomy was performed. The heart was exposed and the left descending coronary artery was ligated with a 8-0 Prolene suture.
Immediately after infarction each heart was injected twice intramyocaridally with lOμl of a buffer suspension containing approximately 800 heparin sepharose/alginate microcapsules with 9μg of absorbed recombinant human PDGF-BB protein. Thus, a total of 1600 microcapsules containing 18μg of human PDGF-BB protein were injected into each rat heart. The lungs were then inflated and the wound was closed in layers. Three weeks later, cardiac function was assessed using a variety of parameters including left ventricular pressure (LVP), dP/dT (a measure of cardiac contractility), negative dP/dT (a measure of relaxation of the cardiac muscle) and tau (the relaxation constant) (see Figure 12). In rats injected with PDGF-BB microcapsules, a 25% increase in left ventricular pressure was detected (see Figure 12). Moreover, cardiac contractility /relaxation increased 2.5 - 3 -fold while the relaxation constant, tau, was decreased by approximately 3 -fold (Figure 12). Thus, a significant improvement in all parameters was detected in rats injected with PDGF-BB microcapsules.
EXAMPLE 5 - Directed Delivery of Angiogenic Factors Using Biocompatible Threads
Regulating the growth of new vessels from existing vasculature (angiogenesis) that effectively bypass an arterial lesion requires strict spatial and temporal control.
Angiogenic factors, such as those described in the preceding examples, work by providing a gradient of angiogenic factor that stimulates the chemotaxis and proliferation of endothelial cells, and their supporting cells towards the source of the factor.
Today, most efforts to stimulate the growth of new vessels involve the injection of proteins into or near affected areas. Such injections can result in the spread of the angiogenic factor over a large area, greatly diminishing their efficacy, and can dilute the angiogenic stimulus over a large region resulting in an unorganized hodge-podge of new vessels that do not provide any therapeutic benefit.
To solve this problem, biocompatible absorbable threads containing angiogenic factors can be employed to provide a small, highly localized and orderly gradient of angiogenic factors in the appropriate and crucial areas. This enables the creation of a
"molecular road map" that directs the growth of new vessels from around the site of the arterial occlusion to join again at a point below or downstream of the blockage. To
achieve this, absorbable surgical threads can be coated with the appropriate angiogenic factors (e.g., PDGF-BB, FGF-2, VEGF-A and PDGF-B). Such threads can then be surgically placed at the site of arterial occlusion such that they provide a clear spatial direction and gradient of angiogenic factor(s) to direct the generation of new vessels around the block.
The biocompatible threads can be coated with one or several angiogenic factors to allow delivery of growth factor or growth factor combinations that provide the optimal angiogenic stimulus. Moreover, such threads can be engineered to release certain growth factors at specific rates and at specific times that may help mimic the natural angiogenic process more closely.
EXAMPLE 6 — Treatment of Ischemia Using Angiogenic Expression Plasmids
Figure 14 shows a variety of expression plasmids encoding angiogenic factors that can be administered directly to localized areas of tissue to promote angiogenesis. To show that the plasmids encode biologically active PDGF-BB protein, supernatant from 293T cells transiently transfected with the PDGF-BB expression plasmid was added to NIH 3T3 cells growing under serum free conditions. Seventy two hours later cells were trypsinized, spun down and counted using a hemocytometer. The results showed that the PDGF-BB supernatant specifically and potently induced the proliferation of NIH3T3 cells.
To analyze cardiac function following administration of expression plasmids in vivo, test animals (e.g., rats) can be injected with control vs. angiogenic plasmids (e.g., PDGF-BB expression plasmids) following myocardial infarction. To achieve this, test animals can be anesthetized and intubated. The chest wall is opened and a myocardial infarct is created by tying off the anterior descending artery. 180μg of control or test expression plasmid is injected into the heart wall in a volume of 20μl. Cardiac function is assessed 3 weeks post injection. Animals are sacrificed, the heart is removed and efficiency of plasmid uptake is assessed by staining with X-gal. The size of the infarct and the extent of angiogenesis is quantified.
Claims
1. A method of promoting angiogenesis comprising delivering PDGF-BB to a localized area of tissue in an amount effective to induce angiogenesis within the area of tissue.
2. The method of claim 1, wherein the PDGF-BB is delivered in combination with one or more other angiogenesis-promoting factors.
3. The method of claim 2, wherein said one or more other angiogenesis- promoting factors is selected from the group consisting of PDGF-AA, M-CSF, GM- CSF, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, neuropilin, FGF-1 , FGF- 2(bFGF), FGF-3, FGF-4, FGF-5, FGF-6, Angiopoietin 1, Angiopoietin 2, erythropoietin, BMP-2, BMP-4, BMP-7, TGF-beta, IGF- 1 , Osteopontin, Pleiotropin, Activin, Endothelin-1 and combinations thereof.
4. The method of claim 1 or 2, wherein the angiogenesis-promoting factor(s) is administered locally in the form of a protein composition.
5. The method of claim 1 or 2, wherein the angiogenesis-promoting factor(s) is delivered in association with a polymer.
The method of claim 5, wherein the polymer comprises a matrix.
7. The method of claim 6, wherein the matrix is selected from the group consisting of heparin sepharose/alginate, chitosan/tricalcium phosphate sponge, poly- lactide-glycolide sponge, polylactide glycolic mesh, methyl cellulose, polysulfone, extrudable ethylene vinyl acetate, alginate/poly-L-lysine/alginate and agarose/poly-L- lysine/alginate.
8. The method of claim 1 or 2, wherein the angiogenesis-promoting factor(s) is delivered by expression from isolated DNA encoding the factor following delivery of the DNA to the localized area of tissue.
9. The method of claim 8, wherein the isolated DNA is contained within a vector.
10. The method of claim 8, wherein the DNA is delivered in an adenoviral vector, retroviral vector, adeno-associated viral vector, RNA vector, liposome, cationic lipid, lentiviral vector, AAV or transposon.
11. The method of any one of claims 1-10, wherein the induction of angiogenesis is used to treat ischemia.
12. A method for promoting angiogenesis comprising contacting a localized area of tissue with heparin sepharose-containing microcapsules in an amount effective to induce angiogenesis within the area of tissue.
13. The method of claim 12, wherein the microcapsules comprise heparin sepharose in a form selected from the group consisting of heparin sepharose beads, heparin sepharose beads coated with a single layer of alginate polymer, heparin sepharose coated with poly-ethylene glycol (PEG) polymer, and heparin sepharose beads coated with alternating layers of alginate and PEG.
14. The method of claim 12, wherein the microcapsules range in size from 1- 250 microns.
15. The method of claim 13 , wherein the heparin sepharose beads encapsulate an angiogenic factor selected from the group consisting of M-CSF, GM- CSF, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, neuropilin, FGF-1 , FGF- 2(bFGF), FGF-3, FGF-4, FGF-5, FGF-6, PDGF-BB, PDGF-AA, Angiopoietin 1,
Angiopoietin 2, erythropoietin, BMP-2, BMP-4, BMP-7, TGF-beta, IGF-1, Osteopontin, Pleiotropin, Activin, Endothelin-1 and combinations thereof, or an expression vector encoding said angiogenic factor.
16. The method of claim 15, wherein the angiogenic factor is purified from its native source or produced by recombinant expression.
17. The method of any one of claims 12-16, wherein the microcapsules are contacted with the localized area of tissue by injection or surgical implantation.
18. The method of claim 17, wherein the injection is performed using a catheter based trans-myocardial injection technology (ie. NOGA).
19. The method of claim 15, wherein the angiogenic factor is control released from the microcapsule into the localized area of tissue.
20. The method of any one of claims 12-19, wherein the induction of angiogenesis is used to treat ischemia.
21. A method for promoting angiogenesis comprising contacting a localized area of tissue with a gradient of one or more angiogenic factors or a nucleic acid encoding one or more angiogenic factors, such that directed vascular growth along the gradient is achieved.
22. The method of claim 21 , wherein the directed vascular growth results in interconnection of blood vessels.
23. The method of claim 21 , wherein the directed vascular growth results in intraconnection of blood vessels.
24. The method of claim 21 , wherein the directed vascular growth circumvents blood flow around a blockage within a blood vessel.
25. The method of claim 21, wherein the angiogenic factor or nucleic acid is released in a gradient from a biocompatible material contacted with the localized area of tissue.
26. The method of claim 25, wherein the biocompatible material is a polymer or thread which incorporates the angiogenic factor.
27. The method of claim 26, wherein the biocompatible material comprises an absorbable thread.
28. The method of claim 27, wherein the thread comprises a material selected from the group consisting of polyglyconate monofilament, poliglecaprone 25- (Monocryl), polydiaxonone (PDS II), polyglactin 910, polyglycolic acid, Biodyn gly comer 631 , chromic surgical gut and plain surgical gut.
29. The method of claim 25, wherein the biocompatible material is implanted into the localized area of tissue.
30. The method of claim 21 , wherein the nucleic acid is contained in an 5 adenoviral vector, retroviral vector, adeno-associated viral vector, RNA vector, liposome, cationic lipid, lentiviral vector, AAV or transposon.
31. The method of claim 21 , wherein the one or more angiogenic factors is selected from the group consisting of M-CSF, GM-CSF, VEGF-A, VEGF-B, VEGF-C,
10 VEGF-D, VEGF-E, neuropilin, FGF-1, FGF-2(bFGF), FGF-3, FGF-4, FGF-5, FGF-6, PDGF-BB, PDGF-AA, Angiopoietin 1, Angiopoietin 2, erythropoietin, BMP-2, BMP-4, BMP-7, TGF-beta, IGF-1, Osteopontin, Pleiotropin, Activin, Endothelin-1 and combinations thereof.
15 32. The method of any one of claims 21-31, wherein the induction of angiogenesis is used to treat ischemia.
33. A method for promoting angiogenesis comprising: applying one or more angiogenic factors, or a nucleic acid encoding one or more 20 angiogenic factors, to a biocompatible material to form a treated material; and contacting the treated material with a localized area of tissue, such that the angiogenic factor or nucleic acid is released into the surrounding tissue in a directed gradient.
25.
34. The method of claim 33, wherein the biocompatible material is an absorbable thread.
35. The method of claim 34, wherein the thread is surgically implanted into the localized area of tissue.
30
36. The method of claim 33, wherein the one or more angiogenic factors includes PDGF-BB.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26445701P | 2001-01-26 | 2001-01-26 | |
US264457P | 2001-01-26 | ||
PCT/US2002/001666 WO2002058718A2 (en) | 2001-01-26 | 2002-01-18 | Use of compositions containing pdgf-bb for promoting angiogenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1355659A2 true EP1355659A2 (en) | 2003-10-29 |
Family
ID=23006154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02714757A Ceased EP1355659A2 (en) | 2001-01-26 | 2002-01-18 | Use of compositions containing pdgf-bb for promoting angiogenesis |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1355659A2 (en) |
JP (1) | JP4434584B2 (en) |
AU (1) | AU2002247007B2 (en) |
CA (1) | CA2436076A1 (en) |
WO (1) | WO2002058718A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020072489A1 (en) * | 1998-10-13 | 2002-06-13 | Whitehouse Martha J. | Angiogenically effective unit dose of FGF-2 and method of use |
JP2005168654A (en) * | 2003-12-09 | 2005-06-30 | Kissei Pharmaceut Co Ltd | Growth factor-bonded low molecular weight modified heparin |
FR2891149B1 (en) | 2005-09-26 | 2007-11-30 | Biodex Sarl | PHARMACEUTICAL COMPOSITION WITH A HEALING ACTION COMPRISING A SOLUBLE DEXTRANE DERIVATIVE AND A PLATELET DERIVED GROWTH FACTOR. |
EP1948210A4 (en) * | 2005-11-08 | 2010-07-14 | Found Biomedical Res & Innov | Method of treatment for ischemic heart disease |
FR2914191A1 (en) * | 2007-03-29 | 2008-10-03 | Proteins & Peptides Man | ANGIOGENIC COMPOSITION |
CN102196822A (en) * | 2008-09-26 | 2011-09-21 | 阿道恰公司 | Complex consisting of polysaccharide and an HBP |
WO2010078624A1 (en) * | 2009-01-07 | 2010-07-15 | Vegenics Limited | Materials and methods for the treatment of hypertension |
GB201504665D0 (en) * | 2015-03-19 | 2015-05-06 | Cell Therapy Ltd | Composition |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4849407A (en) * | 1986-08-13 | 1989-07-18 | Zymogenetics, Inc. | Biologically active mosaic proteins |
US5705485A (en) * | 1987-09-18 | 1998-01-06 | Ethicon, Inc. | Gel formulations containing growth factors |
US4950483A (en) * | 1988-06-30 | 1990-08-21 | Collagen Corporation | Collagen wound healing matrices and process for their production |
NZ237832A (en) * | 1990-04-17 | 1994-05-26 | Curative Tech Inc | Coating a prosthetic surface with mammalian cells |
AU6778794A (en) * | 1993-04-29 | 1994-11-21 | Washington University | Use of platelet-derived growth factor to improve collateral circulation |
WO2000041732A1 (en) * | 1999-01-19 | 2000-07-20 | The Children's Hospital Of Philadelphia | Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof |
-
2002
- 2002-01-18 WO PCT/US2002/001666 patent/WO2002058718A2/en active Application Filing
- 2002-01-18 JP JP2002559052A patent/JP4434584B2/en not_active Expired - Fee Related
- 2002-01-18 CA CA002436076A patent/CA2436076A1/en not_active Abandoned
- 2002-01-18 AU AU2002247007A patent/AU2002247007B2/en not_active Ceased
- 2002-01-18 EP EP02714757A patent/EP1355659A2/en not_active Ceased
Non-Patent Citations (1)
Title |
---|
See references of WO02058718A2 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002247007B2 (en) | 2006-12-07 |
WO2002058718A2 (en) | 2002-08-01 |
WO2002058718A3 (en) | 2003-04-17 |
JP2005506279A (en) | 2005-03-03 |
JP4434584B2 (en) | 2010-03-17 |
CA2436076A1 (en) | 2002-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Winn et al. | Gene therapy approaches for modulating bone regeneration | |
CA2410901C (en) | Methods and compounds for controlled release of recombinant parvovirus vectors | |
ES2206342T3 (en) | MEDICAL DEVICE THAT INCLUDES A SYNTHETIC SURFACE THAT HAS NUCLEIC ACID FOR IN VIVO INDUCTION OF ITS ENDOTELIALIZATION. | |
US20030139333A1 (en) | Methods and compositions for promoting angiogenesis | |
US20080031923A1 (en) | Biologic Replacement for Fibrin Clot | |
JP2006524691A (en) | Genetic modification of targeted regions of the cardiac conduction system | |
CA2433936A1 (en) | Localized myocardial injection method for treating ischemic myocardium | |
CN1198675A (en) | Medicine comprising HGF gene | |
Tepper et al. | Gene therapy in plastic surgery | |
AU2002247007B2 (en) | Use of compositions containing PDGF-BB for promoting angiogenesis | |
US20080102059A1 (en) | Treatment for arthritis | |
AU772857B2 (en) | Method of inducing angiogenesis | |
AU2002247007A1 (en) | Use of compositions containing PDGF-BB for promoting angiogenesis | |
WO1989007944A1 (en) | Device for site directed neovascularization and method for same | |
EA019099B1 (en) | Method for targeted transgene delivery in myocardium of a patient with myocardial ischemia | |
CN1630538A (en) | Stimulation of vascularization with VEGF-B | |
ES2434257T3 (en) | Non-polymeric hematopoietic cell clots for active agent delivery | |
JP2014218509A (en) | Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy | |
WO2001087312A1 (en) | Polyethylene glycol (peg) polymers for the promotion of angiogenesis | |
Vranckx et al. | 15 Gene Transfer of Growth Factors for Wound Repair | |
Wang et al. | In vitro circadian ANP secretion by gene transferring cells encapsulated in polycaprolactone tubes: gene chronotherapy | |
WO2007059303A2 (en) | Compositions for coordinated vegf and pdgf expression, and methods of use | |
Davidson | 13 Gene Therapy of Wounds | |
EP1773373A2 (en) | Method for modulating, regulating and/or stabilizing angiogenesis | |
EP1556494A2 (en) | Bicistronic vector encoding a vegf and an fgf, use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030801 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
17Q | First examination report despatched |
Effective date: 20060421 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20081110 |